Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer

G. W. Sledge, N. Robert, Joseph A. Sparano, M. Cogleigh, L. J. Goldstein, D. Neuberg, E. Rowinsky, C. Baughman, W. McCaskill-Stevens

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Based on their single-agent activity in metastatic breast cancer, paclitaxel (Taxol; Bristol-Myers Squibb Company, princeton, NJ) and doxorubicin have been alternated and combined in Eastern Cooperative Oncology Group studies to identify a tolerable dose and schedule. A pilot trial in patients who had received no more than one prior chemotherapy regimen alternated paclitaxel 200 mg/m2 and doxorubicin 75 mg/m2 every 3 weeks. Seven of 12 patients had objective (complete plus partial) responses. A second (phase I) trial combined doxorubicin as an intravenous push and paclitaxel as a 24-hour continuous infusion. To evaluate the effect of the schedule on toxicity, the drug administration sequence (doxorubicin→paclitaxel or paclitaxel→doxorubicin) was alternated both between and within patients. Initial doses were paclitaxel 150 mg/m2 and doxorubicin 50 mg/m2 in six patients, with a subsequent six patients receiving 175 and 60 mg/m2, respectively. Dose-limiting mucositis was seen at the second dose level when paclitaxel preceded doxorubicin, suggesting an important role for the administration sequence in determining toxicity (and possibly efficacy) in this regimen. These results support the sequence of doxorubicin 50 mg/m2 followed by paclitaxel 150 mg/m2 as the maximum tolerated dose. This combination has been incorporated as a treatment arm in an ongoing randomized prospective phase III Intergroup trial. By comparing the combination with both drugs as single agents (with crossover to the opposite agent at disease progression), investigators will attempt to assess response, toxicity, and time to progression as well as the degree of cross- resistance between the two agents. Given the poor prognosis of patients with advanced breast cancer, the three arms also will be evaluated in terms of patients' quality of life.

Original languageEnglish (US)
Pages (from-to)105-108
Number of pages4
JournalSeminars in Oncology
Volume22
Issue number3 SUPPL. 6
StatePublished - 1995
Externally publishedYes

Fingerprint

Paclitaxel
Doxorubicin
Breast Neoplasms
Appointments and Schedules
Mucositis
Maximum Tolerated Dose
Drug-Related Side Effects and Adverse Reactions
Disease Progression
Quality of Life
Research Personnel
Drug Therapy
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

Sledge, G. W., Robert, N., Sparano, J. A., Cogleigh, M., Goldstein, L. J., Neuberg, D., ... McCaskill-Stevens, W. (1995). Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer. Seminars in Oncology, 22(3 SUPPL. 6), 105-108.

Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer. / Sledge, G. W.; Robert, N.; Sparano, Joseph A.; Cogleigh, M.; Goldstein, L. J.; Neuberg, D.; Rowinsky, E.; Baughman, C.; McCaskill-Stevens, W.

In: Seminars in Oncology, Vol. 22, No. 3 SUPPL. 6, 1995, p. 105-108.

Research output: Contribution to journalArticle

Sledge, GW, Robert, N, Sparano, JA, Cogleigh, M, Goldstein, LJ, Neuberg, D, Rowinsky, E, Baughman, C & McCaskill-Stevens, W 1995, 'Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer', Seminars in Oncology, vol. 22, no. 3 SUPPL. 6, pp. 105-108.
Sledge GW, Robert N, Sparano JA, Cogleigh M, Goldstein LJ, Neuberg D et al. Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer. Seminars in Oncology. 1995;22(3 SUPPL. 6):105-108.
Sledge, G. W. ; Robert, N. ; Sparano, Joseph A. ; Cogleigh, M. ; Goldstein, L. J. ; Neuberg, D. ; Rowinsky, E. ; Baughman, C. ; McCaskill-Stevens, W. / Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer. In: Seminars in Oncology. 1995 ; Vol. 22, No. 3 SUPPL. 6. pp. 105-108.
@article{56feddba136948a2b07b1c1666a8e97b,
title = "Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer",
abstract = "Based on their single-agent activity in metastatic breast cancer, paclitaxel (Taxol; Bristol-Myers Squibb Company, princeton, NJ) and doxorubicin have been alternated and combined in Eastern Cooperative Oncology Group studies to identify a tolerable dose and schedule. A pilot trial in patients who had received no more than one prior chemotherapy regimen alternated paclitaxel 200 mg/m2 and doxorubicin 75 mg/m2 every 3 weeks. Seven of 12 patients had objective (complete plus partial) responses. A second (phase I) trial combined doxorubicin as an intravenous push and paclitaxel as a 24-hour continuous infusion. To evaluate the effect of the schedule on toxicity, the drug administration sequence (doxorubicin→paclitaxel or paclitaxel→doxorubicin) was alternated both between and within patients. Initial doses were paclitaxel 150 mg/m2 and doxorubicin 50 mg/m2 in six patients, with a subsequent six patients receiving 175 and 60 mg/m2, respectively. Dose-limiting mucositis was seen at the second dose level when paclitaxel preceded doxorubicin, suggesting an important role for the administration sequence in determining toxicity (and possibly efficacy) in this regimen. These results support the sequence of doxorubicin 50 mg/m2 followed by paclitaxel 150 mg/m2 as the maximum tolerated dose. This combination has been incorporated as a treatment arm in an ongoing randomized prospective phase III Intergroup trial. By comparing the combination with both drugs as single agents (with crossover to the opposite agent at disease progression), investigators will attempt to assess response, toxicity, and time to progression as well as the degree of cross- resistance between the two agents. Given the poor prognosis of patients with advanced breast cancer, the three arms also will be evaluated in terms of patients' quality of life.",
author = "Sledge, {G. W.} and N. Robert and Sparano, {Joseph A.} and M. Cogleigh and Goldstein, {L. J.} and D. Neuberg and E. Rowinsky and C. Baughman and W. McCaskill-Stevens",
year = "1995",
language = "English (US)",
volume = "22",
pages = "105--108",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "3 SUPPL. 6",

}

TY - JOUR

T1 - Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer

AU - Sledge, G. W.

AU - Robert, N.

AU - Sparano, Joseph A.

AU - Cogleigh, M.

AU - Goldstein, L. J.

AU - Neuberg, D.

AU - Rowinsky, E.

AU - Baughman, C.

AU - McCaskill-Stevens, W.

PY - 1995

Y1 - 1995

N2 - Based on their single-agent activity in metastatic breast cancer, paclitaxel (Taxol; Bristol-Myers Squibb Company, princeton, NJ) and doxorubicin have been alternated and combined in Eastern Cooperative Oncology Group studies to identify a tolerable dose and schedule. A pilot trial in patients who had received no more than one prior chemotherapy regimen alternated paclitaxel 200 mg/m2 and doxorubicin 75 mg/m2 every 3 weeks. Seven of 12 patients had objective (complete plus partial) responses. A second (phase I) trial combined doxorubicin as an intravenous push and paclitaxel as a 24-hour continuous infusion. To evaluate the effect of the schedule on toxicity, the drug administration sequence (doxorubicin→paclitaxel or paclitaxel→doxorubicin) was alternated both between and within patients. Initial doses were paclitaxel 150 mg/m2 and doxorubicin 50 mg/m2 in six patients, with a subsequent six patients receiving 175 and 60 mg/m2, respectively. Dose-limiting mucositis was seen at the second dose level when paclitaxel preceded doxorubicin, suggesting an important role for the administration sequence in determining toxicity (and possibly efficacy) in this regimen. These results support the sequence of doxorubicin 50 mg/m2 followed by paclitaxel 150 mg/m2 as the maximum tolerated dose. This combination has been incorporated as a treatment arm in an ongoing randomized prospective phase III Intergroup trial. By comparing the combination with both drugs as single agents (with crossover to the opposite agent at disease progression), investigators will attempt to assess response, toxicity, and time to progression as well as the degree of cross- resistance between the two agents. Given the poor prognosis of patients with advanced breast cancer, the three arms also will be evaluated in terms of patients' quality of life.

AB - Based on their single-agent activity in metastatic breast cancer, paclitaxel (Taxol; Bristol-Myers Squibb Company, princeton, NJ) and doxorubicin have been alternated and combined in Eastern Cooperative Oncology Group studies to identify a tolerable dose and schedule. A pilot trial in patients who had received no more than one prior chemotherapy regimen alternated paclitaxel 200 mg/m2 and doxorubicin 75 mg/m2 every 3 weeks. Seven of 12 patients had objective (complete plus partial) responses. A second (phase I) trial combined doxorubicin as an intravenous push and paclitaxel as a 24-hour continuous infusion. To evaluate the effect of the schedule on toxicity, the drug administration sequence (doxorubicin→paclitaxel or paclitaxel→doxorubicin) was alternated both between and within patients. Initial doses were paclitaxel 150 mg/m2 and doxorubicin 50 mg/m2 in six patients, with a subsequent six patients receiving 175 and 60 mg/m2, respectively. Dose-limiting mucositis was seen at the second dose level when paclitaxel preceded doxorubicin, suggesting an important role for the administration sequence in determining toxicity (and possibly efficacy) in this regimen. These results support the sequence of doxorubicin 50 mg/m2 followed by paclitaxel 150 mg/m2 as the maximum tolerated dose. This combination has been incorporated as a treatment arm in an ongoing randomized prospective phase III Intergroup trial. By comparing the combination with both drugs as single agents (with crossover to the opposite agent at disease progression), investigators will attempt to assess response, toxicity, and time to progression as well as the degree of cross- resistance between the two agents. Given the poor prognosis of patients with advanced breast cancer, the three arms also will be evaluated in terms of patients' quality of life.

UR - http://www.scopus.com/inward/record.url?scp=0029009612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029009612&partnerID=8YFLogxK

M3 - Article

C2 - 7597425

AN - SCOPUS:0029009612

VL - 22

SP - 105

EP - 108

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 3 SUPPL. 6

ER -